Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.

Continuing the discussion on the case of a 17-year-old patient with moderate acne, Heather Woolery-Lloyd, MD, FAAD, provides an overview of the utilization of clascoterone cream, highlighting the application process and its unique mechanism of action.

An expert dermatologist presents the case of a 17-year-old with moderate acne, and discusses the importance of the proper application layering of skin care and prescription products to optimize treatment efficacy.

Highlighting ways to maximize absorption of isotretinoin, Heather Woolery-Lloyd, MD, FAAD provides insights on dietary considerations and the role of micronized and food independent isotretinoin.

Heather Woolery-Lloyd, MD, FAAD reviews the case of a 12-year-old patient with moderate-to-severe acne, focusing on how to navigate appropriate treatment decisions and patient factors that indicate when a patient is an ideal candidate for isotretinoin.

Rocco Serrao, MD, FAAD, addresses potential barriers to access and affordability of narrowband UVB phototherapy and topical medications for vitiligo treatment, while highlighting available resources to assist patients in overcoming these obstacles.

Rocco Serrao, MD, FAAD, discusses a case of a 38-year-old male with progressive vitiligo, exploring potential triggers and exacerbating factors, as well as lifestyle changes and treatment options to manage symptoms and improve quality of life.

Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.

Rocco Serrao, MD, FAAD, a board-certified dermatologist, discusses a case of vitiligo involving a 20-year-old male patient who presents with white patches on his face that have persisted for 6 weeks without any relevant chemical exposures, and emphasizes the importance of providing counseling and support to address the potential impact on the patient's self-esteem and confidence.

In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.

Kristine Kucera, PA-C, MPAS, DHS, and Mickey Bryson discuss Mickey's atopic dermatitis diagnostic process and the ineffective initial treatments, which included topical therapies, homeopathic remedies, and prednisone steroids.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.

Dr. Matthew J. Zirwas, evaluates a 45-year-old woman with worsening, highly itchy dermatitis on her hands and arms, notably her fingertips. He addresses management strategies for her condition, which has deteriorated over four months, leading to painful fissures

Matthew J. Zirwas, MD, , presents a complex case study of a 63-year-old male patient with atopic dermatitis presenting as a chronic, severe pruritic rash on his back, upper arms, and upper thighs. His condition has persisted consistently for the past three months despite a history of intermittent occurrences over several years.

Mona Shahriari, MD, explores potential areas of research that can contribute to continuous improvement in pediatric atopic dermatitis management.

Mona Shahriari, MD, expands on benefits of ruxolitinib in managing itch and inflammation in pediatric atopic dermatitis.

Michael Cameron, MD, identifies comorbidities, lifestyle factors, and educational opportunities AAD guidelines provide insight on for patients with atopic dermatitis.

Michael Cameron, MD, identifies the most important pearls from the latest atopic dermatitis treatment guidelines set forth by the American Academy of Dermatology.

Sonya Kenkare, MD, explains her approach to itch and the support system of multiple specialties to help a pediatric patient with atopic dermatitis.

Sonya Kenkare, MD, details where ruxolitinib fits within the current landscape of pediatric atopic dermatitis treatments.